A recently awarded National Institutes of Health (NIH) grant will help integrate existing structural biology resources at the ALS to better serve users. The funds will help establish a centralized collaborative mechanism, called ALS-ENABLE, that will guide users through the most appropriate routes for answering their biological questions. Read more »
The CRISPR Target-Recognition Mechanism
CRISPR-associated (Cas) proteins have revolutionized gene editing by vastly simplifying the insertion of short snippets of new (“donor”) DNA into very specific locations of target DNA. Now, researchers have discovered how the Cas proteins are able to recognize the target locations with such great specificity. Read more »
Carolyn Larabell to Receive Shirley Award at ALS User Meeting
Carolyn Larabell, Director of the National Center for X-Ray Tomography (NCXT), centered around ALS Beamline 2.1, has been selected by the ALS Users’ Executive Committee to receive the 2017 David A. Shirley Award for Outstanding Scientific Achievement at the ALS. Read more »
Global Blood Therapeutics Uses ALS to Tackle Sickle Cell Disease
Sickle cell disease (SCD), which affects millions of people worldwide, has traditionally been treated with a cytotoxic drug that has a range of negative side effects and variable patient response. Bay Area biopharmaceutical company Global Blood Therapeutics (GBT) is on a mission to develop a better treatment and is using the ALS to help. Read more »
A Bacterial Jigsaw Puzzle Is Solved
Bacterial microcompartments (BMCs) are hollow protein shells that encapsulate enzymes involved in bacterial metabolism. Crystallography studies have provided atomic-resolution views of a fully assembled BMC, revealing basic principles of shell construction for fighting pathogens or bioengineering applications. Read more »
NCAA Drives Formation of Designed Proteins
A noncanonical amino-acid (NCAA) complex has been found to drive the self-assembly of a computationally designed protein. Bpy-ala, which is “noncanonical” because it’s not among the 20 amino acids that occur naturally, has useful properties that could be used to generate novel photoactive proteins. Read more »
Tender X-Rays Map the Double-Layer Potential
In a first-of-its-kind experiment, ALS researchers demonstrated a new, direct way to study the inner workings of a phenomenon in chemistry known as an “electrochemical double layer” that forms where liquids meet solids—where battery fluid meets an electrode, for example. Read more »
ALS Beamstop Device an R&D 100 Finalist
A beamstop device recently developed at the ALS has successfully combined two essential crystallographic functions–capturing the damaging portion of the beam while simultaneously monitoring its intensity–into a single miniaturized package. The technology has been licensed and launched commercially and is also a finalist for an R&D 100 Award. Read more »
Takeda Advances Diabetes Drug Development at the ALS
Type 2 diabetes mellitus (T2DM), characterized by abnormally high blood glucose levels, affects hundreds of millions of people worldwide. In the pursuit to better treat this disease, the human receptor protein GPR40 has been identified by pharmaceutical company Takeda as a potential new drug target.
Genentech Uses ALS Crystallography for Therapeutic Antibody Research
Genentech has developed a unique one-armed antibody, onartuzumab, which is now in late-stage clinical trials in multiple cancer types. The company used crystal structures obtained at ALS Beamline 5.0.2 to demonstrate the mechanism of action of this unique potentially therapeutic antibody. Read more »
- « Previous Page
- 1
- …
- 5
- 6
- 7